Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of oral hexavalent reassortant rotavirus live attenuated vaccine (Vero cell) in healthy infants
CTR20250157Phase 2Active
- Sponsor
- Sinovac Biotech Ltd.
- Start
- Jan 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of oral hexavalent reassortant rotavirus vaccine, live, attenuated (Vero cell) in rotaviral diarrhea, sponsored by Sinovac Biotech Ltd.. Started Jan 2025; status: active.
02
Drugs
oral hexavalent reassortant rotavirus vaccine, live, attenuated (Vero cell)
03
Conditions
rotaviral diarrhea
Beyond the preview
Go deeper on CTR20250157.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250157.